Article
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com.
All News
Article
Severe and fatal outcomes with coronavirus infection are often the result of the downstream damage that follows the viral infection.
Article
Modifiable lifestyle choices can impact long term health. A recent study shows that usual and increased physical activity can results in less hospitalization amongst the the general population.
Article
Dr. Len Calabrese from the Cleveland Clinic delivers this week's Tuesday Nite Rheumatology Grand Rounds, entitled "IL-6 in Health and Disease: Where Rheumatology Meets COVID-19".
Dr. Calabrese provides a comprehensive review of IL-6 biology, and discusses IL-6 signaling, IL-6 roles in health, exercise, infection, innate and adaptive immunity as pertains to both rheumatology and the management of coronavirus infection.
Article
Hydroxychloroquine has been a dominant news item since the start of the COVID-19 crisis, with a great deal of misconceptions by those who don't know or use or take the drug. HCQ leaped to the headlines on March 19th when President Trump endorsed the drug as being “approved” by FDA. Of course at that time, it was still only approved for SLE, RA and malaria and it wasn't until 2 weeks later (March 31st) that the FDA issued an "emergency use authorization" allowing the use of either chloroquine or HCQ for treatment of severe, hospitalized patients with COVID-19.
To provide clarity and evidence - here are some of the facts you need to know.
Dr. John Cush
Tweet
Anakinra studied in COVID(+) ARDS (nonICU) pts w/ high CRP L or ferritin; 29 high dose Anakinra vs 17 controls. At day 21, more survival with anakinra 90% vs. Controls 56% (p=0·009). Anakinra also more improved CRP+resp function (72 vs 50%) https://t.co/wxjlQG44Oc
Dr. John Cush
Tweet
The RheumNow Podcast is up - The Beat Goes On.... anakinra, nr-AxSpA, Smoking & GPA, PSS guidelines, IFNa, COVID and IL-6, HCQ,QTc, and Thromboses https://t.co/BsaALcHclv
Dr. John Cush
Tweet
European Medicines Agency (EMA), FDA and Health Canada have all issued warnings about the use of hydroxychloroquine & chloroquine in coronavirus, stating they should only be used in drug studies or hospitalized pts. https://t.co/HT39sT31Rq
Dr. John Cush
Tweet
American Hospital Association (AHA), in a new report, projected a loss of $202.6 billion from COVID-19 expenses and lost revenue for US hospitals and health systems from Mar 1 to Jun 30—about $50 billion in losses each month. https://t.co/pidOduwnDb
Dr. John Cush
Tweet
Anakinra works in CPPD. Metanalysis of biologics use finds 74 pts Rx with anakinra for refractory dz (85%) or w/ contraindications (23%). Anakinra resp seen in 81% of acute and 43% of chronic CPPD pts. Few adverse events reported (4.1%) https://t.co/PwJO4ta6i7
Dr. John Cush
Tweet
COVID-19 Does alot of Damage via thrombotic complications - a role for complement or autoantibody mediated thrombotic microangiopathy? #COVID19 https://t.co/33R8WxE5C0
Dr. John Cush
Tweet
Grand Rounds tomorrow at Rutgers - Im Lecturing on “Disease Modifying and Biologic Use for COVID-19 & the Cytokine Storm Syndrome”
https://t.co/FYsr77a68Z
Meeting ID: 934 0443 3549
Ronan Kavanagh
Tweet
Random thought about virtual clinics. Beginning to think that phone just as good as a stop gap as video. Less performative, more relaxed, and less tiring. Rheumatology is mainly (mainly) about history esp for those patients you know well.
k dao
Tweet
“Middle-high level of RF-IgM could lead to false-positive reactivity of SARS-CoV-2 IgM “
As more people want SARS-CoV2 antibody testing, I am afraid this will give people a false sense of security @RheumNow
@ACRheum
NCBI - NLM - NIH https://t.co/vkjWRJQV27
Dr. John Cush
Tweet
Check out a great Grand Rounds by Dr. Len Calabrese @LCalabreseDO on "IL-6 in Health & Disease" - great 30 min lecture and great Q&A session - Bravo Lenny! https://t.co/eWTKotQya3
Dr. John Cush
Tweet
Case report of a stable GPA patient treated with pred and Rituxan on 3/5, developed COVID Sxs next day, progressed to high fever, resp failue, mech ventilaion, Rx with antivirals, HCQ; extubated day 20, negative PCR x2 and discharged day 29. https://t.co/SSSKRbYK2R
Dr. John Cush
Tweet
Italian study of 1193 Psoriasis pts, there were 17 biologic (TNF, UST, IL17 IL23) treated COVID cases. When compared to 19 local nonPSO/Nonbiologic pts. PsO had more Sxs (OR 3.4), more hospitalizations (OR 3.6), but no difference in ICU admission or death https://t.co/6LR857Ksdk
Dr. John Cush
Tweet
5 reasons Telehealth is here to stay: 1) Fast adoption fostered by technology; 2) Lowered regulatory hurdles; 3) Improved financial reimbursements; 4) Video Telehealth can be built upon; & 5) Untapped potential with adoption by Pts and MDs https://t.co/UMeRyUtKnK
Dr. John Cush
Tweet
European Commission has approved Cosentyx (secukinumab) for Rx of adult patients with active non-radiographic axial spondyloarthritis (nr-axSpA) based on results of the Phase III PREVENT trial. (NOT yet FDA/US approved for nr-axSpA) https://t.co/DAWWoG6MJP
Dr. John Cush
Tweet
World Scleroderma Found Recs on COVID 1) SSc w/ Lung dz may be at risk; 2) Cont Rx & avoid SSc lapse in Rx; 3) SSc pts dont need testing unless Sx+; 4) ACE/ARBs BP meds continued; 5) Initiating preventative Rx w/ HCQ is not recommended https://t.co/8BUE6tLLTi
